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Summary In vivo DNA damage and repair was induced by nicotinamide (NAM) in adenotype 12 virus-
induced mouse sarcoma A12B3 and sarcoma F inoculated into CBA mice. DNA damage, NAM and NAD
concentrations were measured after in vivo exposure to NAM, in tumours and spleens by alkaline elution and
by HPLC analysis. Our results indicate that NAM between 100-1000 mg kg-' causes a high level of in vivo
DNA strand breaks in tumours and normal tissues in mice bearing the immunogenic sarcoma A12B3 but not
in the non-immunogenic sarcoma F. The repair process was also delayed by the NAM treatment probably
owing to inhibition of the DNA repair enzyme, poly(ADP-ribose)polymerase, as evidenced by accumulation of
NAM and NAD. These data are consistent with NAM having a mechanism of action as a radiosensitiser at
least in part by DNA repair inhibition. In addition, it should also be considered that high doses ofNAM might
cause considerable complications to normal tissue in tumour-bearing individuals.
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Nicotinamide (NAM), the amide derivative of nicotinic acid
(niacin, vitamin B3) is the main precursor for the formation and
support ofthe cellular pool ofNAD (Bernofsky, 1980; Olsson
et al., 1993). NAM is considered relatively non-toxic at gram
doses (Zackheim et al., 1981) and it has been used clinically to
treat pellagra (Green, 1970), schizophrenia (Greenbaum, 1970)
and to prevent type I diabetes mellitus (Elliot and Chase, 1991).
NAM has also been shown to be a potent radiosensitiser in vitro
and in vivo (Jonsson et al., 1984a; Kjellen et al., 1988; Horsman,
1995). This enhancement of radiation response by NAM is
believed to be due to an increased tumour blood flow which in
turn increases oxygenation of radioresistant hypoxic cells
(Chaplin et al., 1991; Kjellen et al., 1991; Horsman et al.,
1989, 1995) and/or by inhibition ofDNA repair via the nuclear
enzyme poly(ADP-ribose)polymerase (PARP, EC 2.4.2.30)
(Ben Hur et al., 1984; George et al., 1986). Furthermore,
these radiosensitising effects only occur at relatively high NAM
levels of50-100 mg kg-1 which is far above the threshold limit
value ofNAM dietary intake (i.e. 20 mg per individual).
NAD is essential for cellular ATP production, maintenance
of the cells' redox potential, and as a substrate for PARP and
for the other ADP-ribose transfer reactions (for review see
Althaus and Richter, 1987). The PARP enzyme is a DNA-
binding enzyme with two zinc fingers in the DNA-binding
domain (De Murcia et al., 1989; Molinete et al., 1993). The
enzyme activity has been associated with DNA repair,
apoptosis, cell proliferation, cell differentiation and genome
surveillance (Althaus and Richter, 1987; Satoh et al., 1994;
Kaufman et al., 1993; Dai et al., 1987). PARP is activated by
DNA strand breaks, which results in consumption of NAD
(Jonsson et al., 1984b; Rawling et al., 1993) by producing long-
branched polymers ofthe ADP-ribose moieties and free NAM
(De Murcia et al., 1988). NAM, benzamide and 3-aminoben-
zamide (3aBAM) are all potent inhibitors of PARP at doses
above 10-100uM (Rankin et al., 1989) by preventing
production of polymer and reduction of the NAD pool after
induction of DNA damage (Lautier et al., 1990, 1994; Uchida
et al., 1988).
The potential of NAM as a radiosensitiser is currently
being evaluated in several clinical trials (Kaanders et al.,
1995). However, there have been a number of disturbing
toxic side-effects reported in the cancer patients receiving
therapeutic doses of NAM (ESTRO, 1994; van der Maazen
et al., 1995). In order to understand better the contribution of
the possible modes of action of NAM at increasing blood
flow or inhibiting DNA repair, we have studied DNA
damage and the NAD pool as indicators of toxic end points
in CBA mice with or without transplantable mouse sarcoma
tumour lines (i.e. sarcoma A12B3 and sarcoma F). The levels
of DNA damage and DNA repair were evaluated in vivo to
emphasise the potential importance of these parameters, in
understanding the mechanisms of radiosensitisation and
normal tissue toxicity induced by NAM.
Materials and methods
Chemicals
NAD was from Boehringer Mannheim (Germany),
3-aminobenzamide (3aBAM), thymidine, proteinase K and
dimethyl sulphoxide (DMSO) were from Sigma Chemical Co.
(St Louis, MO, USA), Triton-X 100 was from Eastman
(Kodak, Rochester, NY, USA) and RPMI-1640 medium was
supplied from Gibco (USA). NAM was purchased from E
Merck (Darmstadt, Germany) and was administered i.p. after
dilution in 0.9% sodium chloride solution (0.01-0.02 ml g-
1
body weight) at a dose of 10-1000 mg kg-'. 3aBAM was
dissolved in 50% DMSO and was injected i.p. (5 Ml g-' body
weight) at doses of 100, 600 and 1000 mg kg-'.
Cell and tissue sampling
In this study 10- 15-week-old CBA mice were inoculated with
an immunogenic mouse sarcoma line (adenotype 12 virus,
A12B3) (Olsson et al., 1995) or the sarcoma F line (Alison et
al., 1991). The tumours were inoculated (one tumour per
animal, subcutaneous, rough suspension) in the right flank
(A12B3) or in the back (sarcoma F) 12-14 days before the
experiments were performed. The final tumour weights were
in the range of 200-500 mg. The animals were treated
according to the Swedish and the UKCCCR guidelines for
humane treatment of laboratory animals and the experiments
were approved by the ethical committee at the University
Hospital in Lund, Sweden.
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The animals were sacrificed at the indicated time points
after injection of NAM, and samples of spleen and tumour
tissues were collected. Parts of the fresh tissue samples were
immediately processed into a cell suspension by gently
homogenising the tissues with a Pasteur pipette in ice-cold
homogenising buffer (15 mM Tris, 60 mM sodium chloride,
0.34 M sucrose, 10 mM 2-mercaptoethanol and 10 mM
EDTA, pH 7.4 at 4°C) (Olsson et al., 1995). The average
cell density was 5 x 106 cells ml- 1 for tumour (50-00 mg)
and 5-10 x106 cells ml- 1 for spleen ( 50 mg tissue). The
cell suspensions were used for determining DNA damage by
analysis of alkaline elution.
Cell suspensions of tumour and spleen were also frozen at
-80°C after addition of 10% DMSO. Before analysis frozen
cell suspensions were rapidly thawed at 37°C and layered
directly on polycarbonate filters for alkaline elution. There
was no significant difference between fresh and frozen cell
suspensions when analysed by alkaline elution. Samples of
spleen and tumour were collected and washed in ice-cold
saline and, after addition of 600 ,l perchloric acid (PCA),
were frozen in liquid nitrogen followed by storage at -80°C
for later analysis of NAD and NAM content.
Alkaline elution assay for DNA single strand breaks
The alkaline elution assay was carried out as described earlier
(Olsson et al., 1995). Briefly, a 200 ul cell suspension from
tumour, prepared in homogenising buffer and representing
1 x 106 cells, was layered onto 2 gm pore size and 25 mm
diameter polycarbonate filters (Millipore), lysed by 4 ml of
2 M sodium chloride+0.04 M EDTA +0.2% sarkosyl
+0.5 mg ml-' proteinase K (pH 10.0), washed with 2.5 ml
0.02 M EDTA (pH 10.0) and eluted in the dark by 0.01 M
sodium EDTA (pH 12.3) at a flow rate of 0.038 ml min-'.
Fractions were collected every 60 min for 5 h and they
represented the single strand damaged DNA that eluted
under the above conditions. After the elution, the filter-
bound DNA was processed and the DNA was measured
which represented the undamaged fraction of DNA retained
on filters.
NAD and NAM analysis by HPLC
These procedures have been described in detail elsewhere
(Olsson et al., 1995). The weights of the frozen tissue
samples were registered (50- 100 mg), and the samples were
thawed in 600 Mtl 1.8 M PCA (w/v) on ice for NAD and
NAM determinations by HPLC. Thymidine (Thd, 25 ,ul
2.4 mM) was added before homogenisation as an internal
standard, and the samples were centrifuged at 14 000 g to
remove insoluble material. The supernatant (0.5 ml) was
neutralised by addition of 150 Ml 2 M potassium carbonate
solution and after another centrifugation at 14 000 g the
supernatant was ready for analysis by HPLC. The NAD
analysis was performed in a 3 gm C18 column
(83 mm x 4.3 mm i.d., Perkin Elmer Corp., Norwalk, CT,
USA) with a four-pump Perkin Elmer (410 LC) system
having a variable UV detector (LC-95) and an integrator
(LCI-100). Baseline separation was obtained within less than
12 min, when a water solution containing ADP-ribose,
AMP, NADP, NAM, NAD and dThd were analysed. The
general operating conditions were as follows: flow rate,
1.0 ml min-1; mobile phase, 1.4-1.8% methanol for 3.5 min
and 5% for 10 min; temperature, 20-25°C; recycling time
between runs, 10 min; detection at 254 nm.
The level of NAM in tissue was determined as the NAM
concentration in the sample divided by the tissue weight. The
detection limit was below 5 pM which corresponded to 25-
30 pM in the tissue sample. NAD pools were determined as
the NAD concentration divided by the tumour weight. The
corrected NAD value, divided by the peak area of the
internal standard (dThd), was expressed as a percentage of
the NAD concentration in control tumours (A12B3,
229+ 38 pM, n= 19 and sarcoma F, 210+27, n= 13).
Experimental design and statistics
Any effect of variation in the initial tumour weights (i.e.
range, 200-500 mm3) was controlled by always including
1 -3 non-treated tumour-bearing animals in each separate
experiment involving evaluation of NAM treatment of
tumour-bearing animals (i.e. 6 10 animals). The animals
were randomly assigned into different dose groups including
controls, and the results were calculated as the percentage of
the controls in each specific experiment. The separate
experiments were then pooled as controls (non-treated) and
NAM-treated groups for statistical analyses of an overall
effect.
All data were converted to percentage of controls for
analysis and presentation. Calculations were carried out by
SPSS statistical software. For comparison between NAM
doses at any time point, analysis of variance (Anova) was
used, and for comparison between two groups the Duncan
test was used.
Results
In vivo DNA damage in tumour tissue induced by NAM
The exposure of CBA mice bearing mouse sarcoma A12B3 to
a single dose of NAM at 100 or 1000 mg kg-' (i.p.), in the
absence of any other DNA-damaging agent, resulted in a
statistically significant induction of DNA strand breaks in
tumour tissue at 1.5 h after injection (10-20% of control
DNA retained on filter), when monitored and quantified with
alkaline elution (Figure la). However, at a NAM dose of
10 mg kg-', there was no statistically significant induction of
DNA strand breaks in the A12B3 sarcoma line (Figure la).
CBA mice bearing mouse sarcoma F were much less affected
by NAM with significantly different DNA damage levels
being only around 85-90% of the control values at 100 and
1000 mg kg-' (Figure lb). In addition the DNA repair for
the sarcoma A12B3 was delayed with less than 25% of the
induced damage repaired 24 h after NAM injection of
1000 mg kg-' and about 50% of the induced damage
remained after 48 h (Figure la). A similar pattern was
observed from the 100 mg kg-1 dose of NAM where it was
not possible to measure the repair until 8 h after injection
(Figure la) and the DNA damage was still 50% of control
level after 24 h.
Elevated NAM levels in A12B3 sarcoma
The delay in DNA repair in sarcoma A12B3 at a dose of 100
and 1000 mg kg-' NAM (Figure la) may be a result of
inhibition of the DNA repair enzyme PARP. Our results
have clearly shown that the NAM concentration measured by
HPLC (see Material and methods) was above the reported
IC50 value for PARP in vivo (IC50 = 100 pM, Rankin et al.,
1989), at both 100 and 1000 mg kg-1 (Figure 2). When NAM
levels in tumour tissue (sarcoma A112B3) declined to a level
close to 100 pM the DNA repair was initiated (Figure la). At
10 mg kg-' there was also a significant elevation of NAM
tumour levels compared with control tumours, but the tissue
concentration neither reached PARP-inhibiting levels nor was
enough to induce a significant amount of DNA damage.
NAD pools in tumour tissue
To investigate whether the PARP enzyme was inhibited in
tumour tissue after NAM exposure, the NAD pools, as an
indirect measurement of the PARP activity, were determined
at 1.5, 4, 24 and 48 h after injection of NAM (Figure 3). If
the PARP enzyme was inhibited by NAM levels in vivo, then
NAD pools would be expected to increase because PARP
consumes NAD as a co-substrate during its participation in
DNA repair. In such a way the NAD pools can serve as an
indirect measure of PARP activity because DNA damage
stimulates this enzyme activity to consume NAD.Nicotinamide-induced DNA damage and repair in mice
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Figure 2 NAM concentration in CBA mouse tumours (A12B3,
analysed by HPLC) after in vivo exposure to NAM at (0)
10mgkg-1; (El) 100mgkg-1 and (A\) 1000mgkg-1. Indicated
area shows control tumour levels (95% confidence interval of
mean 19gM, n=9). Each data point shows the mean+s.e. of 3-8
tumour-bearing animals.
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Figure 1 In vivo DNA damage and repair in 1
NAM administration. DNA retained on filters
alkaline elution of tumour cell suspensions
A112B3 and (b) sarcoma F, transplanted int(
animals were treated with (O>) 0, (0) 10, I
1000mg NAM kg- 1 body weight and sacrifice(
points. Each data point represents the ave
tumour-bearing animals. There was a stati
difference (P<0.05, Anova) for both A12B3
when treated in vivo with NAM doses of 100
compared with the control group. *Stati:
difference (P<0.05, Duncan test) between tun
NAM at 100mgkg-1 compared with tum
1000mgkg- 1
Table I NAD levels and DNA damage in tuI
sarcoma A12B3) measured by HPLC and al
Material and methods) after injection of a single
100, 600 or 1000mgkg-
3aBAMa 3aBAM
Time n 100mgkg-' n 600mgkg--
NAD pools as % ofcontrolb value
l.5h 4 100+13 4 90±17
4h 3 102±10 3 96±27
DNA retained on filter as % ofcontrol value
1.5h 4 98.1±7.9 3 90.3 ± 9.7
4h 4 108.4±21.2 3 84.6± 19.6
aMean ±s.d. bControl animals were injected
cSignificant difference from non-exposed control
Duncan test.
The NAD pools were significantly highe
after injection of 1000 mg kg-1 in both tumc
with unexposed tumours (NAD levels be
170% ofcontrol tumours, Figure 3). The N)
tumours exposed to 1000 mg kg- ' NAM,
higher at 1.5 h but they returned to contr
injection, and there was even a slight decreE
control levels after 24 h. This reduction may reflect PARP
activity and consumption ofNAD during DNA repair (Figure
la). At the 1000 mg kg-' dose, the pools were back to control
levels in both tumour lines after 24 h which corresponded well
to the repair ofstrand breaks (Figure la and b).
Any significant difference from control levels in tumours
exposed to 10 mg kg-' was not detected at any time point.
tumour tissue after This was expected since there was no induction of DNA
was evaluated by strand breaks that could activate PARP (Figure 1), and the
from (a) sarcoma tumour level of NAM was not high enough to inhibit the
o CBA mice. The PARP enzyme. Moreover, there was only minor induction of
(UI) 100 and (A\) DNA damage assessed by alkaline elution or alteration in
d at indicated time NAD pools determined in tumours exposed to 3aBAM, a
rage+s.e. of 3-8 well defined inhibitor of PARP (Table I), which may exclude
istically significant the possibility that DNA damage was induced as a result of
and F sarcomas
and 1000mg kgs inhibition of PARP (IC50
= 5.4 gM in vivo, Rankin et al.,
stically significant 1989) and DNA repair.
nours treated with
ours treated with In vivo, DNA damage in normal spleen tissue
To investigate whether the induction of DNA damage was a
result of the presence or absence of tumours, normal spleens
mour tissue (mouse originating from CBA mice without tumours, and spleens
Ikaline elution (see from mice carrying sarcoma A12B3 or sarcoma F tumours,
dose of 3aBAM at were analysed by alkaline elution after exposure to single
doses of NAM at 10, 100 and 1000 mg kg-'. The A12B3
3aBAM sarcoma-bearing animals had similar levels ofDNA damage in
n 1000mgkg their spleens compared with tumour tissues from the same
mouse strain at 1.5 h, but the repair was quicker (when
5 88 ±6C compared with tumour tissues (Figure 4), i.e. the half repair
5 91 ± 7 time was <4 h). This fact was interpreted to indicate that the
induction of DNA damage by NAM is an immediate event
even though the tissues are exposed to NAM for a relatively
5 93.1 4.2 long period of time (Figure 2; Horsman et al., 1993).
5it 93.ID4.2 Nevertheless, spleens from mice carrying the sarcoma F had
with 100rl P<DM50. only a minor but statistically significant increase in DNA
[tumours, P<0.05, damage at 1.5 h compared with tumour tissue (50-65% for
spleen vs 85-100% for tumour, Figure lb and 5). Spleen
tissue from non-tumour-bearing animals did not show any
significant induction of DNA damage at any dose (Figure 5),
which supports the conclusion that tumour burden is essential
r at 1.5 h and 4 h for induction of DNA damage by NAM in spleen tissue.
aur lines compared
-tween 131% and
AD pool in A12B3 Discussion
was significantly
^ol levels 4 h after The data reported in this study contribute two important
ase compared with observations to our understanding of how NAM could
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Figure 4 DNA damage and repair measured by alkaline elution
in spleen tissue from tumour-bearing animals (sarcoma A12B3).
Tumour-bearing CBA mice were treated with NAM at doses of
(O) no exposure, (0) 10, (O) 100 and (A) lOOOmgkg-1, and
sacrificed at indicated time points after the drug was admini-
strated. Results are presented as means+s.e. of 3-6 animals.
*Statistically significant difference (P<0.05, Duncan test)
compared with the control group.
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Figure 3 NAD pools in tumour tissue (a) Al2B3 mouse sarcoma
and (b) mouse sarcoma F as a function of time after injection
(i.p.) of NAM at (El) 100 and (A) 1000mg NAMkg- . NAD
pools are expressed as a percentage of control+ s.e. of 3-7
exposed animals at each data point (unexposed tumours: A12B3
tumours mean: 225+44pM, n=18 and F tumours mean:
210+27pM, n= 13. Indicated areas show 95% confidence
interval of mean). NAD content was analysed by HPLC (see
Material and methods).
radiosensitise or induce toxic side-effects; namely (1) NAM
can by itself, without co-administration of radiation, induce
DNA damage and inhibit DNA repair at doses that are
known to radiosensitise, and therefore, increasing tumour
blood flow and overcoming tumour hypoxia is not the only
radiosensitising mechanism that NAM can modulate; and (2)
NAM can induce DNA damage in normal tissue of tumour-
bearing animals which may in turn contribute to its toxic
side-effect profile.
Our results could have been influenced by differences in
tumour biology such as hypoxia or necrosis. However, we
have considered this variable by always including non-treated
tumour-bearing animals as a control over variations in
tumour physiology for each separate experiment. As a
consequence, our data has indicated that within the tumour
weight range of 200-500 mg there was no measurable
influence of the effects of tumour size on the NAM treatment.
The predominant radiosensitising mechanism of NAM is
believed to be through increased tumour blood flow and
oxygenation leading to an increase in radiation-induced DNA
damage (Horsman et al., 1989; Lee et al., 1993; Hirst et al.,
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Figure 5 DNA damage in spleens from CBA mice (E ) without
tumour, (E.) with subcutaneously transplanted sarcoma F
tumours, and (E) with subcutaneously transplanted A12B3
sarcoma tumours. The data represents DNA retained on filters as
percentage of control and staples show the mean+s.e. of 3-5
animals. *Statistically significant difference (P<0.05) compared
with non-tumour-bearing animals and **statistically significant
difference (P<0.05, Duncan test) compared with animals with
sarcoma F tumours.
1993). In this study the induction of DNA strand breaks at
NAM doses of 100 mg kg-' and 1000 mg kg-' (Figures 1
and 2) could have been explained by enhanced tumour
oxygenation ofhypoxic cells resulting in increased production
of oxygen radicals. However, this explanation cannot explain
the induction of DNA damage in spleens from tumour-
bearing animals where the tissue is expected to be fully
oxygenated (Figure 5). Moreover, DNA damage induced by
NAM in spleens from tumour-bearing animals had a repair
half-time less than 4 h (Figure 4) compared with >24 h in
tumour tissue (Figure la). This point could be explained if
NAM clears much faster from the spleen than from tumours,
and hence there would be less of an opportunity for NAM to
accumulate and inhibit DNA repair.
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Figure 6 DNA damage in spleen cell suspensions 1.5 h after
injection of NAM at a dose of 1000mgkg- plotted against the
average spleen weight of CBA mice; (Oy) without tumours; (x)
with subcutaneously transplanted sarcoma F tumours; (*) with
subcutaneously transplanted sarcoma A12B3 tumours. Data
points represent means+ s.e., n _ 3 animals. Linear regression
analysis of all the individual data points included gave a
correlation coefficient of 0.885; P<0.001, n= 12.
Another important consideration is that NAM had a
direct dose-dependent effect on DNA damage in spleens and
tumours in tumour-bearing animals (Figures 1 and 5).
Whether NAM produced DNA damage by direct interaction
with DNA, or by NAM triggering some other cellular
metabolic event leading to DNA damage, the consequence
was a fast and huge induction of DNA damage (Figures 1, 4
and 5) similar to the dose-dependent induction of DNA
damage by ionising radiation alone or in combination with
metoclopramide exposure shown earlier in the same
experimental model (Olsson et al., 1995). One plausible
mechanism that could explain these results is that certain
normal tissues susceptible to infiltration by phagocytes may
accumulate DNA damage via activation of the respiratory
burst. Endogenous oxidative stress induced by NAM in
phagocytes would then be the mode of action (Shacter et al.,
1988; Cochrane, 1991). Support for this hypothesis has been
obtained when the size of the spleens from tumour- and non-
tumour-bearing animals were plotted vs the level of induced
DNA damage in the spleens (Figure 6). The increase in
weight of the spleen tissue could have been the result of an
increased number of infiltrating phagocytes and leucocytes as
a consequence of immunogenic tumour burden. The extent of
the immunogenic response and the level of infiltration in the
sarcoma A12B3 and sarcoma F tumours are currently under
investigation in our laboratory. These data could be very
important from a clinical perspective because they indicate
that in the presence of tumour burden, NAM could cause
unexpected side-effects like DNA damage to normal tissues.
The effective dose of NAM on blood flow is reported to
be at concentrations from 100 mg kg-' and above (Chaplin
et al., 1990). Horsman et al. (1993) showed that there is no
significant difference between the radiosensitising effect of
NAM at doses of 100 mg kg-' and 1000 mg kg-1 in a C3H
mammary carcinoma, even though the difference in plasma
and tumour concentrations of NAM was 5- to 10-fold.
These data have suggested an alternative explanation for the
radiosensitising properties of NAM; namely that NAM at
tumour concentrations of 100 juM or higher inhibits the
PARP enzyme (IC50= 30-100 gIM) (Molinete et al., 1993),
which has been shown to be involved in DNA repair (Satho
and Lindahl, 1994). The induced DNA damage at NAM
doses of 100 and 1000 mg kg-' could be a result of PARP
inhibition because of high tumour tissue levels of NAM
(Figure 2), which in turn resulted in elevated NAD levels
(Figure 3) and accumulation of DNA damage (Figure 1).
Later, when NAM was cleared from tumour tissue and
returned to its original, steady-state level, the DNA repair
was initiated (Figures 1 and 2), and a drop in the NAD
pool owing to PARP activity below control levels was
expected and observed (Figure 3). Furthermore, the NAD
pools in tumour tissue 1-2 h after administration of
100 mg kg- or 1000 mg kg-' NAM was increased over
controls presumably owing to PARP inhibition, and thereby,
they decreased towards control levels between 24-36 h
(Figure 3) when PARP was not inhibited and NAD was
consumed.
In another effort to implicate PARP inhibition in the
mode of action of NAM, we have used the more powerful
PARP inhibitor, 3aBAM. It has been demonstrated
previously that when PARP is inhibited by 3aBAM
(IC50= 5.4,M, Rankin et al., 1989) instead of NAM, the
NAD pools are elevated both in vivo and in vitro in normal
tissues (Uchida et al., 1988; Smit and Stark 1994). However,
we could not show any elevation of the NAD pools in
tumour tissues after exposure of tumour-bearing mice to
3aBAM at doses between 100 mg kg-' and 1000 mg kg-'
(Table I). Hence these data suggest that the observed DNA-
damaging effects of NAM treatment as opposed to 3aBAM
treatment are more influenced by NAD metabolism
supplementing NAD pools than by PARP activity which is
3-8 times higher in tumour tissue compared with normal
tissues (Hirai et al., 1983; Pero et al., 1985; Singh, 1991). For
example both 3aBAM and NAM do not 100% inhibit
PARP, and so there would always be a demand for NAD.
NAM treatment would support NAD synthesis whereas
3aBAM treatment could result in NAD pool depletion
especially in the presence of amplified PARP activity.
Lautier et al. (1990, 1994) showed in C3H101/2 cells, that
PARP-inhibiting doses of 3aBAM (100 piM) did not inhibit
NAD catabolism completely after exposure to active oxygen
species even if poly(ADP-ribose) polymer production was
stopped. In addition, there was no effect on the level of DNA
damage or changes in the NAD pool after exposure to NAM
at 10 mg kg-1 (Figures 1 to 3, a dose not sufficient to effect
PARP inhibition or blood flow). Taken together these data
are consistent with the primary effects of NAM treatment
being on NAD metabolism as well as on PARP inhibition
when considering the possible radiosensitising mechanism of
induction of DNA damage.
Abbreviations
3aBAM, 3-aminobenzamide; DMSO, dimethyl sulphoxide; HPLC,
high performance liquid chromatography; i.p., intraperitonally;
NAD, nicotinamide adenine dinucleotide; NAM, nicotinamide;
PARP, poly(ADP-ribose)polymerase; PCA, perchloric acid; SSB,
single strand breaks; dTHd, thimidine.
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